Skip to main content
. 2022 Mar 8;12(3):730–751. doi: 10.1158/2159-8290.CD-21-0385

Figure 5.

Figure 5. JQAD1 causes genome-wide loss of histone H3K27ac enriched at super-enhancers. A, Enhancers were ranked by H3K27ac signal at 0 hours (left) and 24 hours (right) after treatment of Kelly cells with 500 nmol/L JQAD1. Data are representative of two independent treatments and ChIP-seq experiments. B, Log2 fold change in enhancer H3K27ac signal resolved by H3K27ac ChIP-seq in Kelly NB cells at 0 versus 6 hours (left) and 0 versus 24 hours (right). C, Log2 fold change in enhancer H3K27ac signal stratified by super-enhancers and typical enhancers at 6 and 24 hours after treatment of Kelly cells with 500 nmol/L JQAD1. ***, P < 0.0001 by Student t test comparing super-enhancer– and typical enhancer–regulated genes at 24 hours. Bars, SEM. D, Representative gene tracks of Kelly cells treated with JQAD1 at 500 nmol/L for 0 and 24 hours at the HAND2 CRC factor locus. Data are representative of the adrenergic CRC factor loci (HAND2, ISL1, PHOX2B, GATA3, TBX2, ASCL1, and TFAP2β) and two independent treatments and ChIP-seq experiments. See also Supplementary Fig. S4.

JQAD1 causes genome-wide loss of histone H3K27ac enriched at super-enhancers. A, Enhancers were ranked by H3K27ac signal at 0 hours (left) and 24 hours (right) after treatment of Kelly cells with 500 nmol/L JQAD1. Data are representative of two independent treatments and ChIP-seq experiments. B, Log2 fold change in enhancer H3K27ac signal resolved by H3K27ac ChIP-seq in Kelly NB cells at 0 versus 6 hours (left) and 0 versus 24 hours (right). C, Log2 fold change in enhancer H3K27ac signal stratified by super-enhancers and typical enhancers at 6 and 24 hours after treatment of Kelly cells with 500 nmol/L JQAD1. ***, P < 0.0001 by Student t test comparing super-enhancer– and typical enhancer–regulated genes at 24 hours. Bars, SEM. D, Representative gene tracks of Kelly cells treated with JQAD1 at 500 nmol/L for 0 and 24 hours at the HAND2 CRC factor locus. Data are representative of the adrenergic CRC factor loci (HAND2, ISL1, PHOX2B, GATA3, TBX2, ASCL1, and TFAP2β) and two independent treatments and ChIP-seq experiments. See also Supplementary Fig. S4.